About Sangamo Therapeutics
Sangamo Therapeutics is a company focused on pioneering genetic cures, operating within the biotechnology and healthcare sectors. The company's main services include the development of gene-based therapeutics, utilizing technologies in gene therapy, gene editing, cell therapy, and gene regulation to create genomic cures for patients suffering from severe diseases. Sangamo primarily sells to the healthcare industry. It was founded in 1995 and is based in Brisbane, California.
Research containing Sangamo Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Sangamo Therapeutics in 1 CB Insights research brief, most recently on Aug 31, 2021.
Sangamo Therapeutics Patents
Sangamo Therapeutics has filed 340 patents.
Molecular biology, Biotechnology, Genetic engineering, Transcription factors, DNA
Molecular biology, Biotechnology, Genetic engineering, Transcription factors, DNA
Latest Sangamo Therapeutics News
Nov 26, 2023
Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family members and suffered kidney, lung, hearing and heart damage from a rare disease. 26 Nov 2023, 10:23 AM IST 26 Nov 2023, 10:23 AM IST WhatsApp A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs (Bloomberg) -- Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family members and suffered kidney, lung, hearing and heart damage from a rare disease. (Bloomberg) -- Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family members and suffered kidney, lung, hearing and heart damage from a rare disease. Citing the “challenging economic environment” that’s sending shock waves through the biotech industry, Sangamo paused research on an experimental gene therapy — possibly a cure — for Fabry disease. Walter, a 69-year-old retired US Army colonel who’s already had a heart transplant due to the inherited enzyme deficiency, said it’s disappointing to see work stop on yet another potential new medicine. “The promise of a better treatment keeps getting pushed down the road,” he said. Sangamo will finish a current Fabry trial as planned and is seeking funding or a partner for help with moving its studies to the final stage, a spokesperson said. Yet it’s been another bleak year for biotech companies as a closely watched index of stocks, often called the XBI, just passed 1,000 days from its early 2021 peak. The number of companies exploring strategic options — typically a sign of desperation — just hit a record high, according to analysts from Stifel. “Nobody knows where the bottom of this is,” said Sam Fazeli, an analyst at Bloomberg Intelligence. Money for research is getting harder to find: New flows into biotech venture funds are estimated to fall to $23 billion this year from about $31 billion in 2021, the Stifel analysts said. Rising interest rates, threats to prices of new drugs and a post-pandemic letdown have forced biotechs to pull back on research and development. Last year, global pharma R&D spending fell 2.2% to $244 billion, the first drop in a decade, according to Evaluate Pharma, and slowed growth is expected in the coming years. It was just the fourth such decline in almost four decades, according to the PhRMA industry group. The sector has seen “serious slimming down of pipelines at the small end,” Evaluate said in its August report. Crucial Work Big drugmakers have increasingly moved into areas that used to be biotech’s domain — like cancer and rare diseases — seeking profits from drugs that aren’t easily replaced by competitors. French drugmaker Sanofi is boosting R&D spending, while Eli Lilly & Co., maker of blockbuster weight-loss drugs, increased this year’s R&D budget by $600 million. But the industry giants can’t replace the crucial work done by smaller biotech companies, said Derek Lowe, a longtime drug researcher who writes the industry blog “In the Pipeline.” In many cases, biotech companies handle risky early-stage research that big drugmakers may invest in if it shows promise. Biotech companies often take on challenges that are a bit “out there,” Lowe said. Big manufacturers “let the little companies take a crack at it and see how it goes.” Gone is the pandemic enthusiasm that drove Covid shot-maker Moderna Inc.’s 12-month trailing price as high as 188 times diluted earnings per share from continuing operations in June 2021. Now the company is expected to report losses on an adjusted basis over the next year, and more than half the analysts covering it don’t recommend buying shares. An industry slowdown was inevitable, Fazeli said. Firms are shifting their strategies in response. Unable to find investors who can provide more funds, small biotechs are skipping the long shots to focus on sure bets that are more likely to generate income soon or attract a deal with a bigger drug company, said John LaMattina, a former head of R&D at Pfizer Inc. That means less creativity in the sector that gave rise to Covid shots, life-saving gene therapies and other treatments for once-fatal diseases. Those include Merck & Co.’s Keytruda, which first took shape about two decades ago at biotech company Organon & Co. Today the drug has treated more than 1 million patients with more than 20 different cancers, generating some $21 billion in sales last year. Medicine Paucity “The concern is that in three or four years from now there will be a paucity of innovative medicines,” said Jeff Jonas, former chief executive officer of the biotech company Sage Therapeutics Inc. “There is potential for the early ecosystem to suffer.” The impact is hitting companies like Charles River Laboratories International Inc. that does work including early safety research on rats that precedes human testing. The firm has been involved in studying more than 80% of all US-approved drugs in the past three years. Biotech companies that once investigated four or five products at a time now just have enough funding for two, said Jim Foster, Charles River’s chief executive officer. The result: organic revenue is expected to grow about 6% this year, roughly half its 2022 level. “People are reprioritizing, being more judicious,” Foster said in an interview. “We are a canary in the coal mine.” Lab space vacancies in the Boston biotech industry hub have hit a 10-year high, according to the real estate firm Colliers. For the first time, there’s about 5 million square feet of space on the market, up from 300,000 two years ago. IRA Fears Biotech’s woes could be a problem for big drugmakers, said Lowe, the pharma blogger: a smaller crop of candidates for big drug companies to buy later on. Those drugmakers need new products to make up for older ones that will be facing competition when their exclusivity runs out. Aging drugs are also eligible for Medicare price negotiations under the Inflation Reduction Act, President Joe Biden’s signature legislation. Drugmakers have said that the law effectively shortens their products’ most profitable period, and that some early development programs will have to be sacrificed. All that is bad news for Walter, the former colonel who founded the National Fabry Disease Foundation. Twice a month, the Hillsborough, North Carolina, resident sits for three hours getting enzyme replacement through an IV. Jerry WalterPhotographer: Cornell Watson/Bloomberg Before running short of money, Sangamo was pursuing a one-time treatment aimed at fixing the gene flaw responsible for the disease, meaning Fabry patients wouldn’t need those twice-monthly infusions. Those who got it in a trial “continue to report improvements in their quality of life,” the company said. “We believe this is an important potential medicine and are doing everything in our power to still get this to patients in need,” the Sangamo spokesperson said in an email. The treatment could have been “revolutionary,” had work on it continued, Walter said, adding he hopes that Sangamo can resolve its funding issues. (Updates with company comment in final section. A previous version of this story corrected the frequency of patient’s infusions.) More stories like this are available on bloomberg.com ©2023 Bloomberg L.P.
Sangamo Therapeutics Frequently Asked Questions (FAQ)
When was Sangamo Therapeutics founded?
Sangamo Therapeutics was founded in 1995.
Where is Sangamo Therapeutics's headquarters?
Sangamo Therapeutics's headquarters is located at 7000 Marina Blvd, Brisbane.
What is Sangamo Therapeutics's latest funding round?
Sangamo Therapeutics's latest funding round is PIPE.
How much did Sangamo Therapeutics raise?
Sangamo Therapeutics raised a total of $16.19M.
Who are the investors of Sangamo Therapeutics?
Investors of Sangamo Therapeutics include AAC Capital Partners, LODH Private Equity Partners, JAFCO Life Science Investment, The Stephens Group, Palladin Group and 3 more.
Who are Sangamo Therapeutics's competitors?
Competitors of Sangamo Therapeutics include Sagimet Biosciences, La Jolla Pharmaceutical Company, Sirnaomics, Dicerna Pharmaceuticals, CODA Biotherapeutics and 7 more.
Compare Sangamo Therapeutics to Competitors
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.
Bar Harbor Biotech is a life sciences company spun-out from The Jackson Laboratory to develop gene expression products and services. Bar Harbor Biotech's technology focuses on real-time quantitative polymerase chain reaction (PCR), an established technique for gene expression used in disease research, molecular diagnostics, drug discovery, and other fields of biology research.
InsectiGen, Inc. is a biotechnology company focused on discovery and development of biopesticides. Founded by Clifton Baile, PhD and Michael Adang PhD, InsectiGen has licensed IP from the University of Georgia associated with modified proteins form the intestine of insects that enhance natural insecticides produced by Bacillus thuringensis (Bt).
AthenaES specializes in the development and commercialization of advanced biotechnology-based products. Throughout its eleven year history, the company has maintained a broad perspective for applying its core competency, the use of proteins and enzymes for commercial applications, to develop products. As such, the company currently markets its products and services through two business units and maintains an exploratory R&D group. The Athena Enzyme Systems Group aims to provide specialty reagents and proteins for the production and recovery of recombinant proteins along with providing contract R&D services. Products include: Expression Media, Serum-free Media, Protein Refolding kits, and the PDQ Protease Assay. This business unit also aims to provide specialized contract research, development and manufacturing services for the production of recombinant proteins. The Athena Environmental Services Group designs, develops and manufactures environmentally responsible products. Products developed include: The Bilge Pill, a biodegradable cleaning product for the removal of oil in boat bilges, and a plant nutrient supplement used in hydroponics, hobby gardens and horticulture that replaces conventional fertilizers, and the Sting Thing, an enzyme-based invertebrate sting treatment product. More recently, this group developed and has introduced a water-soluble, reversible glue, MagiGlue. The Athena Exploratory Science Group has the mission to pursue research with the potential for commercial, environmental and social impact. These projects are far reaching in their scope and represent high risk, high-value projects.